| What to know | Reported value | Planning use |
|---|---|---|
| Replacement | Replaced monthly; a ring stays in for 28 days, then a new one is used | Note the insertion date and plan the next supply visit around it. |
| Two phase III trials | About 30% reduction in HIV risk | Expect partial protection, not a guarantee. |
| Two open-label extension trials | Estimated protective levels of 39% and 62% | Encouraging, but weigh these alongside the main trials rather than instead of them. |
| Modeling estimate | May be more than 50% effective when used consistently | Consistent use is what moves the figure upward; it is an estimate, not a trial result. |
| European Medicines Agency opinion | July 2020; women 18 years and older when oral PrEP is not feasible | Age and the suitability of oral PrEP frame who the label addresses. |
Figures come from a peer-reviewed review of the ring and the EATG report on the European Medicines Agency opinion.
The dapivirine vaginal ring is a monthly HIV prevention option that gave about 30% lower HIV risk in two phase III trials. Its protection depends on keeping a ring in place and replacing it on schedule.
It is one of several choices described in our guide to women’s HIV prevention. The sections below turn the trial figures into decisions first, then explain how the ring works.
What the trial results mean when choosing a method
The ring lowers risk; it does not remove it. In two phase III trials it provided about 30% reduction in HIV risk, according to the peer-reviewed review in PMC. A study in almost 2000 women in sub-Saharan Africa found the ring lowered the chances of HIV infection by more than one third over 24 months compared with placebo, as reported by EATG.
Higher numbers exist, but they carry conditions. Two open-label extension trials estimated protective levels of 39% and 62%, and modeling suggests the ring may be more than 50% effective when used consistently. These are estimates from follow-on studies and models, so they describe what is possible with steady use rather than what every user should expect.
The WHO position fits this picture. As described in the same review, the WHO recommended the ring as an additional prevention choice for women at substantial risk of HIV, not as a replacement for other options.
How to use this in a decision
- The ring suits women who want a monthly option. The European Medicines Agency opinion framed it for women 18 years and older when oral PrEP is not feasible, so it is most relevant where daily pills are not workable.
- Treat the 30% figure as the baseline. It comes from the main phase III trials; the higher estimates depend on extension designs or on consistent use.
- Compare with other long-acting options. If you are weighing the ring against a different product, read about injectable PrEP for women before choosing.
- Keep timing in mind. If an exposure has already happened, prevention before the event is no longer the question; see PEP for women after HIV exposure.
Side effects, safety and who should check first
The European Medicines Agency considered the ring’s side effects manageable, according to EATG’s account of its opinion. The product leaflet and a clinician are the right place to review the full list of reported effects, because the detail varies by label and setting.
Comfort is a separate question from safety. In a three-month trial of 96 postmenopausal women, 72% found the ring very easy to use and 4% reported interference with daily activities, according to the PMC review. That group differs from the women the ring is meant for in HIV prevention, so read the result as a signal about handling, not a prediction for every user.
Pregnancy and breastfeeding
The DELIVER trial found women can safely use the dapivirine vaginal ring for HIV PrEP in the third trimester of pregnancy. A sister trial confirmed it is also safe during breastfeeding. Both findings are reported by Magee-Womens Research Institute.
Open questions worth raising with a provider
- Younger women. The European Medicines Agency said uncertainties about the benefit in younger women needed addressing, which is why its original approval covered women 18 years and older.
- Resistance. The same opinion flagged uncertainty about the risk of resistance. Ask a provider how HIV testing fits into your use of the ring.
- Contraindications. Check the product leaflet for any condition that rules the ring out before starting.
Using the ring month to month
The ring is inserted in the vagina for 28 days, after which it should be replaced by a new one, as EATG notes. Because it slowly releases dapivirine over a month-long period and is replaced monthly, the routine is one scheduled change rather than a daily task. Ask the provider to show you how to insert it, and follow the leaflet for the details.
The monthly rhythm makes timing the main habit to build. Record the date each ring goes in, and arrange the next supply before the 28 days end so there is no gap.
When circumstances make use harder
Adherence is not only a matter of memory. An analysis of data from the MTN-020 (ASPIRE) trial found that a recent experience of a social harm was associated with lower adherence to dapivirine ring use, as summarized by PrEPWatch. Since the ring only helps when it is in place, it is sensible to discuss with a counselor how to plan for situations at home or in the community that make steady use difficult.
Where the ring is approved and available
Approval and availability are different things, and both are growing unevenly. The European Medicines Agency gave its original opinion in July 2020 for women 18 years and older, and described the ring as intended for use outside the EU, according to EATG. The first national approval came in 2021 from the Medicines Control Authority of Zimbabwe.
A review noted the ring was going through the regulatory review process in several African countries. More recently, PrEPWatch lists national guidelines from Mozambique, Lesotho, Eswatini and Kenya (2025 to 2026) that include the dapivirine vaginal ring among the products delivered.
Outside those programs, do not assume access. The same PMC review described oral PrEP as the only widely available HIV prevention product in the United States apart from male and female condoms. The practical step is to ask a local clinic or national HIV program whether the ring is stocked and who is eligible.
How the ring works
The dapivirine vaginal ring is a silicone ring containing an HIV medication called dapivirine, a description given by Magee-Womens Research Institute. The drug blocks the ability of HIV to make copies of itself inside healthy cells.
The ring releases dapivirine slowly over a month, which is why one device covers the whole replacement period. In form it resembles vaginal rings used for hormone delivery, such as those used for management of menopausal symptoms, per the PMC review. That familiarity helps explain why trial participants could handle it without special equipment.
Protection beyond HIV
The ring is an HIV medication, and the trial and approval figures above describe HIV risk only. None of the cited results claims protection against other sexually transmitted infections, so a woman who wants that protection needs a separate method; the PMC review notes male and female condoms as the other widely available HIV prevention products.
The same applies to pregnancy. The DELIVER finding concerns whether HIV PrEP use is safe in the third trimester, not whether the ring prevents pregnancy, and it should not be read as contraception.
Frequently asked questions
Who developed the dapivirine vaginal ring?
The ring was developed by the International Partnership for Microbicides, according to the PMC review.
How does the ring compare with oral PrEP?
Studies show oral PrEP is more than 90% efficacious when used correctly, while the ring provided about 30% reduction in two phase III trials. The figures come from different studies and describe different things, so they are not a head-to-head result. The WHO describes the ring as an additional choice for women at substantial risk.
Is the ring the first long-acting HIV prevention product for women?
The European Medicines Agency called it the first long-acting technology approved for HIV prevention in women, as EATG reports. Other long-acting products have followed since.
